Maxim Group Rates Context Therapeutics (CNTX) buy
Maxim Group maintains a buy rating on CNTX with a $4 price target, as the stock trades near $0.679, a 489.10% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Maxim Group rated Context Therapeutics Inc. ($CNTX) "buy" with a $4 price target on June 16, 2026.
Since the rating, $CNTX is up 0.0% after 1 week, down 6.2% after 1 month and down 63.1% to date (from the $0.65 close on Jun 16, 2026).
CNTX
Context Therapeutics Inc.
Key Points
- Maxim Group reiterated its buy rating on CNTX with a $4 price target on June 16, 2026.
- Maxim Group's $4 price target implies 489.10% upside from Context Therapeutics Inc.'s ($CNTX) current $0.68 share price.
- CNTX shares are trading around $0.68, with insider activity showing recent purchases by top executives.
- Institutional investors like Soleus Capital and Octagon Capital have shown interest in CNTX, adjusting their holdings recently.
Get $CNTX trade alerts by text
We text you when insiders, Congress or big funds trade $CNTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Context Therapeutics Inc. alert may contain errors. Disclosures
Maxim Group has reiterated its buy rating on CNTX, setting a price target of $4. Analyst Jason McCarthy of Maxim Group made this call on June 16, 2026, as the stock trades around $0.68.
Other Institutional Activity in CNTX
Soleus Capital Management, L.P. entered the scene with 6,963,141 shares valued at about $18.2 million. Octagon Capital Advisors LP also took a position with 5,250,000 shares worth approximately $13.8 million. Meanwhile, Blue Owl Capital Holdings LP trimmed its stake by 2,343,891 shares, leaving it with 5,089,015 shares valued at $13.3 million.
Context Therapeutics Inc. Stock Up 84.5%
Shares of CNTX are trading near $0.68. The stock has been of interest to several institutional investors, reflecting varied strategies in recent holdings.
$CNTX price target
Context Therapeutics Inc. daily closes and this analyst's $4 target. Not advice.
Insider Buying and Selling at Context Therapeutics Inc.
On February 19, 2026, top executives made significant insider purchases. CFO Jennifer Lynn Minai-Azary acquired 275,000 shares, CEO Martin Lehr bought 815,000 shares, and Chief Medical Officer Karen Deborah Chagin purchased 290,000 shares. Additionally, Chief Legal Officer Alex Levit bought 270,000 shares. These transactions were not under any pre-planned trading programs.
Analysts Set New Price Targets
On June 16, 2026, Maxim Group maintained its buy rating on CNTX with a $4 target. Earlier in March, Guggenheim reiterated a buy rating with a $5 target, while Piper Sandler maintained a buy with a $7 target. The consensus among analysts remains bullish, with a strong buy recommendation.
Bottom Line
Maxim Group's reaffirmation of a buy rating for CNTX with a $4 target reflects continued optimism from analysts. Though the stock trades at a modest $0.68, institutional interest and insider buying highlight potential confidence in its prospects. As always, remember that analyst ratings are forward-looking and based on current assessments.
Related Filing Alerts
Source: Maxim Group's rating change on $CNTX (Jun 16, 2026). Written by software, not financial advice. How we make alerts